France's biotech firms prepare exit strategy

19 February 2007

With the outcome of May's presidential elections in France in doubt, biotechnology firms are considering taking part in a "flight of capital" if Segolene Royal becomes the first Socialist party nominee to win election since 1988. The last time a Socialist took over from a center-right administration was in 1981, when many of the major French industrial firms were nationalized by President Francois Mitterrand.

Philippe Pouletty, honorary chairman of France Biotech, the country's biotechnology trade association, told the Financial Times: "if the Socialists were elected and implemented their pre-election promises, a lot of people would say 'enough is enough' and move abroad, just coming back to France for holidays."

As a sign that the French drug industry (LEEM) does not confine its woes to fears of a Socialist administration if Ms Royal defeats the center-right candidate, Nicolas Sarkhozy, Christian Lajoux, the LEEM's president, said: "the financial subjugation of the industry, due to the deteriorating public finances, remains the fundamental problem."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight